2026 Global: Cervical Cancer Diagnostic Market-Competitive Review (2032) report
Description
The 2026 Global: Cervical Cancer Diagnostic Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cervical cancer diagnostic market by geography and historical trend. The scope of the report extends to sizing of the cervical cancer diagnostic market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, Becton Dickinson and Company (BD), Hologic Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., and Carl Zeiss AG dominate the cervical cancer diagnostic market through innovative screening technologies and strategic expansions.
These companies lead with advanced diagnostic tools like HPV testing, Pap smears, and AI-enhanced cytology systems, driving early detection amid rising global incidence rates. Abbott Laboratories excels in molecular diagnostics and immunoassay platforms for precise HPV detection, supporting high-throughput screening in hospitals and labs. BD strengthens its portfolio via the 2022 acquisition of Cytognos, integrating flow cytometry for immune response analysis and minimal residual disease monitoring in cervical cases. Hologic's Genius Digital Diagnostics System, FDA-cleared in February 2024, combines AI algorithms with volumetric imaging to identify pre-cancerous lesions, boosting accuracy and accessibility. Roche (F. Hoffmann-La Roche Ltd. and Roche Diagnostics) offers comprehensive solutions including next-generation sequencing and tissue diagnostics, with recent WHO prequalifications expanding cervical screening reach. QIAGEN dominates HPV DNA testing, a segment holding the largest market share, enabling non-invasive, self-sampling options for broader adoption.
Further innovations include Siemens Healthineers' imaging and lab automation for colposcopy and biopsy workflows, Thermo Fisher's biomarker assays like urine-based tests adaptable to oncology, and Bio-Rad's reagents for liquid-based cytology. Carl Zeiss AG provides optical systems for enhanced visualization during diagnostics, while Quest Diagnostics advances self-collection HPV screening, planning rollout across 2,000 U.S. centers by mid-2025 to target at-risk populations. Collectively, these firms capitalize on North America's 52% market share in 2024, fueled by government programs like the CDC's NBCCEDP and high screening participation over 70%, projecting global growth from USD 9.82 billion in 2025 to USD 15.37 billion by 2034 at a 5.12% CAGR. Their focus on AI, point-of-care, and molecular tools addresses challenges in low-resource regions, improving survival via early intervention.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cervical cancer diagnostic market by geography and historical trend. The scope of the report extends to sizing of the cervical cancer diagnostic market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, Becton Dickinson and Company (BD), Hologic Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., and Carl Zeiss AG dominate the cervical cancer diagnostic market through innovative screening technologies and strategic expansions.
These companies lead with advanced diagnostic tools like HPV testing, Pap smears, and AI-enhanced cytology systems, driving early detection amid rising global incidence rates. Abbott Laboratories excels in molecular diagnostics and immunoassay platforms for precise HPV detection, supporting high-throughput screening in hospitals and labs. BD strengthens its portfolio via the 2022 acquisition of Cytognos, integrating flow cytometry for immune response analysis and minimal residual disease monitoring in cervical cases. Hologic's Genius Digital Diagnostics System, FDA-cleared in February 2024, combines AI algorithms with volumetric imaging to identify pre-cancerous lesions, boosting accuracy and accessibility. Roche (F. Hoffmann-La Roche Ltd. and Roche Diagnostics) offers comprehensive solutions including next-generation sequencing and tissue diagnostics, with recent WHO prequalifications expanding cervical screening reach. QIAGEN dominates HPV DNA testing, a segment holding the largest market share, enabling non-invasive, self-sampling options for broader adoption.
Further innovations include Siemens Healthineers' imaging and lab automation for colposcopy and biopsy workflows, Thermo Fisher's biomarker assays like urine-based tests adaptable to oncology, and Bio-Rad's reagents for liquid-based cytology. Carl Zeiss AG provides optical systems for enhanced visualization during diagnostics, while Quest Diagnostics advances self-collection HPV screening, planning rollout across 2,000 U.S. centers by mid-2025 to target at-risk populations. Collectively, these firms capitalize on North America's 52% market share in 2024, fueled by government programs like the CDC's NBCCEDP and high screening participation over 70%, projecting global growth from USD 9.82 billion in 2025 to USD 15.37 billion by 2034 at a 5.12% CAGR. Their focus on AI, point-of-care, and molecular tools addresses challenges in low-resource regions, improving survival via early intervention.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
